Furthermore, because SLE is characterized by complexities in disease phases, flares, pathological states, treatment effects, etc., the cross-sectional design of our work did not allow us to identify how IL-6 varies during the disease progression. This evidence concerns the gene IL6 and systemic lupus erythematosus.